Craig Lammert, MD
Gastroenterology · Indianapolis, INNPI 1356527733
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $14,375 of the $17,475 with a category attached, or 82.3%. Eli Lilly accounts for 82.3% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $7,500, 2.4 times the $3,125 reported in 2022. Among gastroenterology clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 19 payments — averaging $919.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$14K
- Orphalan Inc$3K
- Perspectum Diagnostics Ltd$100
Across 31 payments — averaging $7287.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ultragenyx Pharmaceutical Inc.$221K
- Amgen$5K
What the payments were for
- Consulting fees$14,37582%
- Speaking & faculty fees$3,00017%
- Food & beverage$1001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 17 | $14,375 |
| Orphalan Inc | 1 | $3,000 |
| Perspectum Diagnostics Ltd | 1 | $100 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CUVRIOR$3,000
- LiverMultiScan$100
How this compares
$17,475 in reported general payments places this provider in the 90th percentile of 323 gastroenterology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 62 | $207,717 |
| Ursodiol | 109 | $24,205 |
| Mycophenolate Mofetil | 88 | $10,713 |
| Sirolimus | 14 | $2,404 |
| Lactulose | 47 | $2,362 |
| Tacrolimus | 16 | $1,963 |
| Budesonide EcBudesonide | 14 | $1,930 |
| Entecavir | 29 | $1,901 |
| Azathioprine | 67 | $1,844 |
| Ethacrynic Acid | 11 | $1,084 |
| Spironolactone | 64 | $884 |
| Omeprazole | 36 | $578 |
| Hydroxyzine Hcl | 12 | $353 |
| Pantoprazole Sodium | 14 | $262 |
| Prednisone | 16 | $170 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Indianapolis
- Douglas RexIndianapolis$557K
- Ajay JainIndianapolis$432K
- Monika FischerIndianapolis$258K
- Naga ChalasaniIndianapolis$255K
- Thomas ImperialeIndianapolis$188K
- Mark GromskiIndianapolis$154K
- David PoundIndianapolis$137K
- Glen LehmanIndianapolis$87K
- Samer GawriehIndianapolis$78K
- Stuart ShermanIndianapolis$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.